To our knowledge, our study is the first that analyzed the relationship between ATXN2 genetic alterations and clinical symptom manifestation (SARA and INAS) and symptom severity in SCA3 patients in detail. The gene discussed is ATXN2; the disease is Spinocerebellar ataxia type 3.